Acknowledging the kind of traction gained by this market, recently published a study report asserts the global Ursodeoxycholic Acid Drug Product Market size is projected to accrue voluminously by 2027 registering a phenomenal CAGR of around 12.0% during the review period (2022 to 2027).
Ursodeoxycholic acid (UDCA) is a naturally-occurring bile acid that is used as a result of its strong hydrophobic properties. UDCA selectively inhibits the binding of certain cholesterol-containing molecules to cell membranes, which results in cholesterol‑lowering and other related therapeutic effects. The effectiveness of UDCA as a treatment for hyperlipidemia and primary biliary cholangitis has been established in clinical studies. Market growth for UDCA will continue to be driven by the expanding prevalence of these indications, particularly in developed markets where there are high rates of diagnosis and awareness. In addition, the availability of generic UDCA products is expected to lower the cost of treatment and increase market growth. As the market continues to grow, UDCA is expected to become an increasingly important treatment option for patients with hyperlipidemia and primary biliary cholangitis.
The report aspects discussed the profile of the top manufacturers of the global Ursodeoxycholic Acid Drug Product Market. These aspects include financial status of major companies, trending advancements and entire market scenario. Growth of the report have examined Ursodeoxycholic Acid Drug Product Market production, demand and growth potential, geographic analysis, as well as current market developments invarious regions and countries.
January 2nd, 2022: Merger of Kalexsyn Inc. into Dipharma Inc.--
Dipharma Francis (“Dipharma”), a global CDMO and a leading manufacturer of APIs and intermediates for generic and contract manufacturing markets, is pleased to announce that Kalexsyn, Inc., a Michigan corporation (“Kalexsyn”) acquired in 2018, has been merged into its 100% owner, Dipharma Inc., a Delaware corporation and member of the Dipharma Group, effective January 01, 2022.
Ursodeoxycholic Acid Drug Product Market is segmented based on the type, applications, companies and regions.
By Type, Ursodeoxycholic Acid Drug Product Market has been segmented into
By Applications, Ursodeoxycholic Acid Drug Product Market has been segmented into
The report offers in-depth assessment of the growth and other aspects of the Ursodeoxycholic Acid Drug Product Market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.
In North America, Epic pharma is the key manufacturer whereas Lannett, Teva and Mylan are top suppliers of Ursodeoxycholic Acid in the US. In China, Falk pharma is the leader with a market share of 81% in the year 2017. In Japan, Mitsubishi Tanabe pharma is the market leader with an approximate market share of 52% in the year 2017. In 2017, with a market share of 86.1% Daewoong pharmaceutical led the market in Korea.
Ursodeoxycholic Acid Drug Product Market highlights the potential growth opportunities in upcoming years, while reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape and other key aspects in the global market. The Global Ursodeoxycholic Acid Drug Product Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
Report Attributes
|
Report Details |
Forecast Period 2022 to 2027 CAGR |
CAGR of 12.0% during the review period (2022 to 2027). |
By Type |
|
By Application |
|
By Companies
|
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, Grindeks and others. |
Regions Covered
|
|
Countries Covered |
|
Base Year
|
2022 |
Historical Year
|
2017 to 2021 |
Forecast Year
|
2022 to 2027 |
Customization Available
|
Yes, the report can be customized as per your needs |
All our reports are customizable to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report to your needs.
What is the study period of this market?
The Relay Market is studied from 2017 - 2027.
What is the growth rate of Ursodeoxycholic Acid Drug Product Market?
The Relay Market is growing at a CAGR of 12.0% over the next 5 years.
Who are the key players in Ursodeoxycholic Acid Drug Product Market?
Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Epic Pharma, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini, Impax, Shanghai Pharma, Grindeks and others.
What region does this Ursodeoxycholic Acid Drug Product Market report covers?
North America (the United States, Canada, and Mexico) Europe (Germany, France, UK, Russia, and Italy) Asia-Pacific (China, Japan, Korea, India, and Southeast Asia) South America (Brazil, Argentina, Colombia, etc.) The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)
What are the significant types of Ursodeoxycholic Acid Drug Product Market?
Synthetic UDCA, Extraction UDCA
What are the major end-use applications of Ursodeoxycholic Acid Drug Product Market?
Gallstone, Hepatopathy, Biliary Disease, Pharmacy, Health Products, Other
Application_List
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.
Reach us with your research requirements and we shall provide the optimum solution to suit your needs.
Discounts available for multiple report purchases.